Publications

2024

Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, et al. Resistance to PRMT5-targeted therapy in mantle cell lymphoma. Blood Adv. 2024;8(1):150-163.
Adeuyan O, Magro CM, Trager MH, Gordon ER, Lapolla BA, Schreidah CM, et al. Plasma cell and neutrophil enriched neovascularization with granulomatous lymphangitis in POEMS syndrome. JAAD Case Rep. 2024;49:125-128.
Omar M, Xu Z, Rand SB, Alexanderani MK, Salles DC, Valencia I, et al. Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images. Mol Cancer Res. 2024;22(4):347-359.
van Wyk AC, Lal P, J Ogunbiyi O, Kyokunda L, Hobenu F, Dial C, et al. Multinational, Multicenter Evaluation of Prostate Cancer Tissue in Sub-Saharan Africa: Challenges and Opportunities. JCO Glob Oncol. 2024;10:e2300403.
Deochand DK, Dacic M, Bale MJ, Daman AW, Josefowicz SZ, Oliver D, et al. Mechanisms of Epigenomic and Functional Convergence Between Glucocorticoid- and IL4-Driven Macrophage Programming. bioRxiv. 2024.
L Medeiros J, Chadburn A, Natkunam Y, Naresh KN. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms. Mod Pathol. 2024;37(4):100441.
Francini E, Nuzzo PV, Fanelli GN. Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring. Cancers (Basel). 2024;16(3).
Hsu H, Zanettini C, Coker M, Boudova S, Rach D, Mvula G, et al. Concomitant assessment of PD-1 and CD56 expression identifies subsets of resting cord blood Vδ2 T cells with disparate cytotoxic potential. Cell Immunol. 2024;395-396:104797.
Smithgall MC, Yemelyanova A, Mathew S, Gogineni S, He B, Zhang T, et al. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024;43(2):134-139.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700